Company profile: Sofie
1.1 - Company Overview
Company description
- Provider of molecular imaging, focused on empowering people with new PET technologies.
Products and services
🔒
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Sofie
Veraxa Biotech
HQ: Germany
Website
- Description: Provider of ADC development solutions, combining targeted antibody discovery and bioconjugation. Offerings include droplet-based microfluidics for functional antibody screening, site-specific conjugation via proprietary bioorthogonal click chemistry to create uniform, stable ADCs, Positional Intelligence genetic code expansion for precise payload placement, and charged payloads to enhance manufacturing, efficacy, pharmacokinetics, and safety.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Veraxa Biotech company profile →
Perspective Therapeutics
HQ: United States
Website
- Description: Provider of radiopharmaceutical cancer theranostics and targeted alpha-particle radiotherapy, including Pb-203 diagnostics and Pb-212 treatment via targeting peptides. Offers clinical programs VMT-α-NET for neuroendocrine tumors and VMT01 for metastatic melanoma, and a proprietary Pb-212 isotope generator to secure key isotopes for clinical trials and commercial operations.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Perspective Therapeutics company profile →
ProfoundBio
HQ: United States
Website
- Description: Provider of antibody-based cancer therapeutics, including antibody-drug conjugates. Clinical-stage pipeline includes Rina-S, a folate receptor alpha-targeting ADC for ovarian and other solid tumors (Phase 2); PRO1160, a CD70-targeting ADC for solid tumors and hematological malignancies (Phase 1/2); PRO1107, a PTK7-targeted ADC with a hydrophilic MMAE-based linker-drug (Phase 1/2); and PRO1286, a bispecific EGFR/cMET ADC (trials anticipated in 2024).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full ProfoundBio company profile →
Cero Therapeutics
HQ: United States
Website
- Description: Provider of cellular immunotherapy centered on a CER T-cell platform that integrates anti-tumor capabilities of the innate and adaptive immune systems into a single T cell, aimed at treating hematologic malignancies and solid tumors.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Cero Therapeutics company profile →
Izotropic
HQ: United States
Website
- Description: Provider of breast CT imaging solutions, offering a high-resolution, 3D Breast CT Imaging System that captures approximately 500 images in a 10-second scan without compression; a robotic-guided Breast CT Biopsy System for imaging and sampling suspicious lesions and tumors for pathology testing; and Breast CT–based breast density measurement using 3D images and algorithms to estimate glandular volumes.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Izotropic company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Sofie
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Sofie
2.2 - Growth funds investing in similar companies to Sofie
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Sofie
4.2 - Public trading comparable groups for Sofie
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →